Atreca Inc logo

BCEL - Atreca Inc Share Price

$14.84 -1.0  -6.3%

Last Trade - 17/01/20

Sector
Healthcare
Size
Small Cap
Market Cap £338.7m
Enterprise Value £185.0m
Revenue £n/a
Position in Universe 3129th / 6416
Bullish
Bearish
Unlock BCEL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BCEL Revenue Unlock BCEL Revenue

Net Income

BCEL Net Income Unlock BCEL Revenue

Normalised EPS

BCEL Normalised EPS Unlock BCEL Revenue

PE Ratio Range

BCEL PE Ratio Range Unlock BCEL Revenue

Dividend Yield Range

BCEL Dividend Yield Range Unlock BCEL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BCEL EPS Forecasts Unlock BCEL Revenue
Profile Summary

Atreca, Inc. is a biotechnology company. The Company is engaged in developing therapeutics drawn from human immune responses, including anti-cancer immune responses. Its portfolio programs are focused on applications in cancer treatment. The Company’s lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using our discovery platform. The Company's Immune Repertoire Capture (IRC) technology, which enables us to accurately reconstruct the original antibody sequences from a single B cell in parallel with other B cells in the sample. Its IRC tracks the co-expression of genes from the same single cell and TCRs are recovered. IRC generates sequence information from the beginning of signal sequences through constant regions of immunoglobulins, delivering variable domains and isotype information.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated June 11, 2010
Public Since June 20, 2019
No. of Shareholders: n/a
No. of Employees: 102
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 27,960,043
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BCEL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to BCEL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.